The reimbursement standards for ‘Revlimid’ in combination with Velcade, and dexamethasone (RVD) for multiple myeloma have been extended. However, reimbursement for the drug as a maintenance therapy still remains unaddressed.

Starting on April 1st, BMS Korea’s Revlimid (lenalidomide) will receive insurance benefits as part of RVd (lenalidomide+bortezomib+ dexamethasone) therapy.

The approval was made 6 months after the agenda passed the meeting of the Cancer Disease Deliberation Committee of the Health Insurance Review and Assessment Service in September last year. However, the maintenance therapy agenda that was deliberated on the same day still remains non-reimbursed.